Cannabis for Chronic Pain: Evidence & Guide

Cannabis interacts with the body's endocannabinoid system (ECS), a complex signalling network that helps regulate pain, inflammation, mood, appetite, and immune function. The ECS consists of cannabinoid receptors (CB1 and CB2), endocannabinoids produced naturally by the body, and enzymes that break them down.

CB1 receptors are concentrated in the central nervous system — the brain and spinal cord — where they modulate neurotransmitter release. When THC binds to CB1 receptors, it reduces the transmission of pain signals from nerves to the brain. This is why THC-dominant products are often used for pain relief, though the psychoactive effects are an unavoidable side effect.

CB2 receptors are found primarily on immune cells and in peripheral tissues. Activating CB2 receptors reduces inflammation by decreasing the production of pro-inflammatory cytokines. CBD has a more indirect effect on CB2 receptors and also interacts with other pain-modulating systems, including TRPV1 (vanilloid) receptors and serotonin 5-HT1A receptors.

THC acts as a partial agonist at both CB1 and CB2 receptors — it binds to and activates them, producing both pain relief and psychoactive effects. CBD acts as a negative allosteric modulator of CB1, meaning it can reduce some of THC's psychoactive effects while potentially enhancing its therapeutic effects. CBD also has independent anti-inflammatory and analgesic properties.

The 'entourage effect' theory suggests that cannabinoids and terpenes work better together than in isolation. Full-spectrum products containing multiple cannabinoids and terpenes may provide more effective pain relief than isolated compounds. However, the evidence for this remains preliminary.

The evidence for cannabis in chronic pain is mixed and the topic remains controversial. Let's look at what the key studies actually show — separating strong evidence from weaker evidence.

For neuropathic pain, the evidence is most consistent. A 2022 living systematic review from the US Agency for Healthcare Research and Quality found moderate-strength evidence that balanced THC:CBD oral spray produced a small improvement in pain severity compared to placebo. Synthetic high-THC products showed a moderate improvement in pain severity. However, the same review found that benefits were offset by significant side effects including dizziness, sedation, and nausea.

Real-world data from the UK Medical Cannabis Registry tells a different story. Multiple studies from this registry have found statistically significant improvements in pain scores, sleep quality, anxiety, and overall quality of life in chronic pain patients prescribed cannabis oils and dried flower. Opioid use also decreased significantly. However, these are observational studies, not randomised controlled trials, so they cannot prove causation.

A 2024 review of 43 randomised controlled trials found that inhaled cannabis significantly reduced pain in chronic pain patients. The same review concluded that medical cannabis may be particularly effective for chronic neuropathic pain — the type caused by nerve damage.

However, the most recent Cochrane review (January 2026) was more cautious. After analysing 21 studies with 2,187 participants, it found no clear evidence for pain relief of 50% or greater with any type of cannabis-based medicine compared to placebo. The authors described the evidence as 'limited in both methodological rigour and clinical relevance.' Most studies were small and only 4 lasted 12 weeks or longer.

The Scottish Intercollegiate Guidelines Network (SIGN) published draft guidance in February 2025 that did not recommend routine use of medical cannabis for chronic non-malignant pain, citing 'very limited evidence of clinically significant improvements in pain.' NICE guidance (NG144, 2019, last reviewed 2025) similarly recommends against offering cannabis-based products for chronic pain outside of clinical trials.

The bottom line: there is a disconnect between what clinical trials show (modest benefits at best) and what many patients and doctors report in the real world (significant improvements). The evidence is strongest for neuropathic pain, weakest for general chronic pain. More high-quality, long-term studies are urgently needed.

Not all chronic pain responds equally to cannabis. Current evidence suggests certain pain types are more likely to benefit than others.

Neuropathic pain (nerve pain) has the strongest evidence base. Conditions like diabetic neuropathy, post-herpetic neuralgia, and nerve injury pain have been the focus of most randomised trials. The combination of THC and CBD, delivered as an oral spray, is the most studied formulation. Typical benefits include modest pain reduction and improved sleep.

Inflammatory pain, such as that caused by rheumatoid arthritis or inflammatory bowel disease, may respond to cannabis primarily through its anti-inflammatory effects. CBD-dominant products are often preferred here to avoid psychoactive effects, though some patients benefit from balanced THC:CBD products.

Fibromyalgia is a complex condition involving nociplastic pain — pain driven by central sensitisation rather than tissue damage. Evidence for cannabis in fibromyalgia is inconsistent. Some studies show improvements in pain and quality of life, while others show no significant benefit. NICE has made a specific research recommendation for CBD in fibromyalgia.

Chronic back pain and musculoskeletal pain are the most common reasons people seek medical cannabis in the UK, but the evidence here is largely observational. Many patients report significant improvement, but high-quality trials in this specific area are limited.

Cancer-related pain may respond to cannabis, particularly when other treatments have failed. Some evidence suggests cannabis can reduce opioid requirements in cancer patients. However, NICE has also made a research recommendation for this area, reflecting the limited evidence base.

Migraine and headache disorders show some promise in early studies, with both THC and CBD potentially reducing frequency and severity. However, evidence is preliminary and more research is needed before firm conclusions can be drawn.

How does cannabis compare to conventional pain treatments? This is a crucial question but one that's surprisingly difficult to answer, because most cannabis trials compare against placebo rather than against active treatments.

Versus opioids: Cannabis appears to have a better safety profile than opioids — no risk of fatal respiratory depression, lower addiction potential, and fewer severe side effects. Several UK registry studies have shown that patients reduce their opioid use after starting cannabis treatment. However, cannabis is not a direct replacement and may be less effective for severe acute pain.

Versus gabapentinoids (gabapentin, pregabalin): These are commonly prescribed for neuropathic pain but have significant side effects including dizziness, sedation, and weight gain. Cannabis may offer similar or slightly better pain relief with a different side effect profile. Some patients find cannabis more tolerable for long-term use.

Versus antidepressants (amitriptyline, duloxetine): These are often used for chronic pain at lower doses than for depression. They can be effective but side effects like dry mouth, constipation, and sexual dysfunction are common. Cannabis may offer an alternative for patients who cannot tolerate these medications.

Versus NSAIDs (ibuprofen, naproxen): NSAIDs are effective for inflammatory pain but long-term use carries risks of stomach ulcers, kidney damage, and cardiovascular events. Cannabis may be a safer option for long-term inflammatory pain management, particularly for older adults.

The key advantage of cannabis is its relatively favourable safety profile compared to many conventional pain medications. The key disadvantage is the inconsistent evidence base, the psychoactive effects of THC, and the lack of standardised dosing guidelines.

Medical cannabis was legalised in the UK in November 2018, following high-profile cases of children with severe epilepsy. Since then, thousands of patients have accessed cannabis-based prescriptions through private clinics — with chronic pain being the most common reason for prescription.

Despite this, official UK guidelines remain cautious. NICE does not recommend cannabis-based products for chronic pain outside of clinical trials. SIGN (Scottish Guidelines) reached the same conclusion in 2025. The NHS prescribing of cannabis for chronic pain is virtually non-existent.

This creates an unusual situation: cannabis for chronic pain is legal by private prescription, recommended against by official guidelines, yet prescribed to thousands of patients who report significant benefits. The Medical Cannabis Clinicians Society (MCCS) has published good practice guidelines that recognise chronic pain as one of the most common and established indications for prescribing.

Clinicians who prescribe cannabis for chronic pain must be on the General Medical Council's Specialist Register. GPs cannot prescribe cannabis-based products for chronic pain on the NHS and are often reluctant to support shared care agreements with private clinics.

The legal position means patients must pay privately for cannabis-based pain treatment. Costs typically range from £150-£300 for an initial consultation, plus £100-£400 per month for medication. Some clinics offer access schemes or reduced pricing for low-income patients.

Despite the cost and the cautious official guidelines, the UK private medical cannabis market continues to grow, driven by patient demand and positive real-world outcomes. The gap between official guidance and clinical practice is likely to narrow as more high-quality evidence emerges.

Cannabis-based medicines are generally well-tolerated, but they are not without risks. Understanding these is essential before considering treatment.

Common side effects: dizziness (up to 30% of users), dry mouth, sedation or drowsiness, nausea, and increased appetite. These are usually mild to moderate and often improve as the body adjusts to the medication. Starting with a low dose and increasing slowly helps minimise these effects.

Psychoactive effects: THC produces a 'high' that some patients find unpleasant or disruptive. This can include euphoria, altered time perception, impaired coordination, and difficulty concentrating. CBD-dominant or balanced products reduce these effects but may also reduce pain relief. Finding the right THC:CBD ratio is a process of trial and error under medical supervision.

Mental health risks: Cannabis can worsen anxiety, paranoia, and psychosis in susceptible individuals. Anyone with a personal or family history of psychosis or bipolar disorder should avoid high-THC products. CBD-dominant products are significantly safer but should still be discussed with a doctor.

Dependence and withdrawal: Around 9% of cannabis users develop cannabis use disorder. Regular use can lead to dependence, and stopping suddenly can cause withdrawal symptoms including irritability, insomnia, loss of appetite, and mood changes. Medical patients are monitored for signs of problematic use.

Drug interactions: Cannabis interacts with the CYP450 enzyme system in the liver, which processes many common medications. This includes blood thinners (warfarin), some antidepressants, anticonvulsants, and sedatives. Your prescribing doctor will check for interactions before starting treatment.

Long-term risks: The long-term safety of daily cannabis use for chronic pain is not fully understood. Potential concerns include impacts on memory and cognition, hormonal effects, and — for smoked or vaped products — respiratory effects. Patients are typically reviewed every 3-6 months to monitor for adverse effects.